Full-Time

Warehouse Manager

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Biotechnology firm specializing in antibody therapies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$95.3k - CA$119.1kAnnually

+ Equity + Annual Bonus

Senior, Expert

Vancouver, BC, Canada

Category
Supply Chain Management
Warehouse Operations
Operations & Logistics
Required Skills
Supply Chain Management
SAP Products

You match the following AbCellera Biologics's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • You hold a bachelor’s degree in supply chain management, logistics, business administration, or a related field and 8 years of experience in warehouse management or a similar role, preferably within a large-scale distribution environment or a Masters degree and 6 years of warehouse experience
  • You have a strong understanding of supply chain management, inventory control, and logistics principles
  • You have proficiency in SAP and other warehouse management systems
  • You thrive in a fast-paced environment with a high level of urgency and evolving priorities, and apply pragmatic, risk-based decision making and problem-solving skills to supply chain management
  • You are an outstanding communicator, team player, and relationship builder, with a demonstrated ability to build, lead, and mentor a high-performing team
Responsibilities
  • Overseeing all aspects of warehouse operations, including receiving, storage, inventory management, and order fulfillment
  • Managing the maintenance and operation of warehouse equipment and ensuring adherence to safety standards
  • Ensuring timely and accurate order fulfillment, meeting customer service expectations, and improving satisfaction levels and collaborating with the transport section to optimize delivery schedules and reduce transportation costs
  • Addressing AbCellerites’ inquiries, feedback, and requests to maintain strong relationships
  • Managing and optimizing the use of the warehouse management system (SAP), ensuring data accuracy and timely updates
  • Coordinating all distribution services, including inbound and outbound logistics, to meet operational and customer requirements as well as ensuring a well-coordinated reception of all materials, items, and products and making sure they are sorted, labeled, and stored per company standards and policies
  • Working closely with the procurement department to align inventory levels with production schedules and customer demand
  • Ensuring compliance with company policies, safety regulations, and legal requirements as well as implementing and monitoring health and safety procedures to maintain a safe working environment

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and licensing its antibody candidates.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could solve the blood-brain barrier challenge in neuroscience.
  • Partnerships with Viking and ArrowMark may diversify revenue and enhance market presence.
  • Expanded collaboration with Eli Lilly could advance immunology, cardiovascular, and neuroscience programs.

What critics are saying

  • Increased competition in T-cell engagers may impact AbCellera's market share.
  • Failure in Biogen collaboration could harm reputation and financial outcomes.
  • Peter Thiel's resignation may lead to strategic shifts affecting investor confidence.

What makes AbCellera Biologics unique

  • AbCellera excels in antibody discovery with a proprietary, integrated technology platform.
  • The company partners with leading firms like AbbVie and Eli Lilly for drug development.
  • AbCellera's focus on multiomics and AI enhances its drug discovery efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

Seeking Alpha
May 1st, 2024
AbCellera partners with PE firms to develop antibody drugs, company creation

AbCellera (NASDAQ:ABCL) has inked an agreement with Viking Global Investors and ArrowMark Partners to develop new antibody drug programs, with an initial focus on immunology.